Navigation Links
Labopharm Comments on Recent Trading Activity
Date:12/12/2008

LAVAL, QC, Dec. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS), at the request of Market Surveillance on behalf of the Toronto Stock Exchange, today commented on the recent trading activity of its common shares. The Company is not aware of any reason for the recent trading activity other than the approaching Prescription Drug User Fee Act (PDUFA) action date for its once-daily formulation of tramadol, by which the U.S. Food and Drug Administration (FDA) could provide final approval for marketing and sale of the formulation in the United States. The PDUFA action date is January 2, 2009. The Company has not yet received any decision from the FDA. When it does, it will issue a press release.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of fac
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
2. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
3. Labopharm announces change to Board of Directors
4. Labopharm Reports Results for Third Quarter Fiscal 2008
5. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
6. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
7. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
8. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
9. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
10. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
11. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ec. 4 Care Investment T...) today announced that its Board of Directors has ...tock. The dividend is payable on December 22, 200... 2009. ,, About Care Investment Trust ,...stment and finance company investing in healthcare...
(Date:12/4/2009)...ISCO, Dec. 4 Medithrive, Inc. has ...pensary in the SF Bay Area by popular vote conduct...ite only three months in operation, the SF Bay com...ocation for accessing medicinal marijuana. ,,...rms the obvious: a dispensary which caters to the ...
(Date:12/4/2009)... Dec. 4 The American As...SA) applauds the Senate for ensuring that the Com...isions remain in the final health reform legislati...ing support to elders, people with disabilities an...ass a health care reform bill that will make it af...
(Date:12/4/2009)...TY, Mo., Dec. 4 The large, two-day...ciation of Free Clinics (NAFC) in Kansas City on W... also for anyone who is uninsured and has not seen... clinic will receive preventive primary care. ,...rge free clinic events this fall in Houston, New O...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chie...selected as a finalist for the "Chief Innovation O...iness with the power of cloud computing. Appy Awar...ve usage of Salesforce CRM or the Force.com platfo...heir sales, marketing, partner, service, support o...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
...oung people appear to be developing the most commo...a dramatic increase in the cost and suffering //ca... overexposure to ultraviolet light from the sun, u...almost always curable and that together afflict 1 ...
... years since the Transplantation of Human Organ Ac...ay with the programme. This has been due to variou...irection and the will to seriously consider this a...idney scandal there is a knee jerk reaction from v...
...ug Digoxin or Digitalis, which comes from the foxg...t efficiently by maintaining the rhythm of the hea...f the drug is changed by the team of researchers f... which works by changing the sugars attached to th...
...s have shown that the efficacy of low-carb diets c... researchers question whether raising protein inta...cent study researchers set out to test the hypothe...ight loss. However some are of the opinion that pr...
...se are crucial factors. But according to the resea...reventive Medicine, // it has been found that calo...ath by heart disease. The finding was based on... done from 1971 to 1975. The participants were gro...
...ould not be a factor in determining transplant el...hown that older heart transplant patients do just ...archers evaluated all 275 adult patients who recei...o 11 years following surgery. Results showed no st...
Other Medicine News:Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3Health News:Finding The Key To Weight Loss! 2
(Date:12/4/2009)..., , RARITAN, N.J., Dec. 4 ...ttention Deficit Hyperactivity Disorder (ADHD), sl...orbidities reported to occur more often in people ...sus those without an epilepsy diagnosis, according...cross the U.S. ,, Findings from " CNS-Related C...
(Date:12/3/2009)..., , MADISON, N.J., Dec. 3 /PRNewswire-Fir... patient,s risk of developing a potentially life-t...armaceutical therapies or chemicals is one of seve...ostics leader Quest Diagnostics (NYSE: DGX ) wil...tology (ASH) Annual Meeting and Exposition, Decemb...
(Date:12/3/2009)..., , WARRENDALE, Pa., Dec. 3 /PRN...demonstrated PACS* injection-record integration ca...of North America in Chicago. The Connect.PACS(TM...cs capabilities of its kind, is the latest release...rmatics Platform . ,, (Photo: http://www.ne...
Breaking Medicine Technology:Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 1Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 1Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 3
Plasmacup SC
Trabecular Metal Modular Acetabular System
BiHAPro Acetabular Cup
Gap II Revision Cup
Medicine Products: